Genprex Stock News

Genprex <> said its collaborators published positive preclinical data for the use of its ONCOPREX Nanoparticle Delivery System to deliver a FAS DNA plasmid to treat

4 names for your penny stocks list this week. The post 4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks

Genprex Inc announced that its collaborators published positive clinical data for the use of Genprex's ONCOPREX Nanoparticle Delivery System for delivery of a FAS DNA plasmid to treat metastatic color

Genprex Inc has announced a plan to accelerate the opening of trial sites for the Acclaim-1 clinical trial, which combines the company's lead product candidate, REQORSA (quaratusugene ozeplasmid) Imm

Genprex Inc (GNPX) shares closed this week 69.5% higher than it did at the end of last week. The stock is currently up 69.5% year-to-date, down 42.8% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $3.62 and as low as $1.51 this week.Shares closed 71.2% below its 52-week high and 89.7% above its 52-week low.Trading volume this week was 67.5% lower than the 10-day average and 8.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 14.5% lower than its 5-day moving average, 34.1% higher than its 20-day moving average, and 2.7% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -26755.6% The company's stock price performance over the past 12 months lags the peer average by 389.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Genprex Inc (GNPX) shares closed today 20.3% lower than it did at the end of yesterday. The stock is currently up 167.2% year-to-date, down 15.7% over the past 12 months, and down 25.5% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 fell 0.0%. Trading Activity Shares traded as high as $3.62 and as low as $1.17 this week.Shares closed 63.9% below its 52-week high and 138.5% above its 52-week low.Trading volume this week was 492.9% higher than the 10-day average and 1829.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 5506.3% The company's stock price performance over the past 12 months beats the peer average by -47.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

The stock price of Genprex Inc (NASDAQ: GNPX) increased by 167.18% in the most recent trading session. This is why it happened.

Genprex Inc (NASDAQ: GNPX) is a clinical-stage gene therapy organization that concentrates on the development of life-changing gene therapies to treat people with diabetes and cancer. The company ann

Shares of Genprex Inc. GNPX, +121.37% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designat

Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA. The post GNPX Stock: 5 Things to Know as Genprex Rockets High

We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. The post 8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT,